ICP
PFE icon

Ilex Capital Partners’s Pfizer PFE Stock Holding History

Ilex Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.11M Buy
+253,878
New +$6.64M 0.13% 68
2025
Q2 		– Sell
-118,007
Closed -$2.99M – 237
2025
Q1 		$2.99M Buy
+118,007
New +$3.09M 0.12% 54

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ilex Capital Partners's PFE Position: Q2 2026 in Review

Ilex Capital Partners opened a new position in Pfizer (PFE) in Q2 2026: 253,878 shares worth $6.11M. The stake represents 0.13% of the portfolio and ranks #68 among its holdings. This is a return to the name: Ilex Capital Partners previously reported a position in PFE as recently as Q1 2025.

Ilex Capital Partners first reported a position in PFE in Q1 2025 and has held it in 2 quarters since. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Ilex Capital Partners held 253,878 shares of Pfizer worth $6.11M as of Q2 2026.
  • Pfizer was a new Ilex Capital Partners position in Q2 2026.
  • Pfizer made up 0.13% of Ilex Capital Partners's portfolio in Q2 2026, its #68 holding.
  • Ilex Capital Partners first reported a position in Pfizer in Q1 2025 and has held it in 2 quarters since.
  • 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Ilex Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.